NCT05101551 2025-05-29
PARPAML
Stanford University
Phase 1 Recruiting
Clinical Trials
5 trialsNCT04207190 2024-11-01
Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 1 Completed
NCT05319249 2024-04-05
NAKIP-AML
German Cancer Research Center
Phase 1/2 Not yet recruiting
NCT02878785 2023-03-29
1565GCC
University of Maryland, Baltimore
Phase 1/2 Completed
NCT01399840 2017-09-15
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
Pfizer
Phase 1 Completed